eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) reconfirmed today that the regulatory
status for anti-amyloid beta (aβ) protofibril antibody leqembi® (generic name: lecanemab) subcutaneous
(sc) autoinjector, explained at the financial disclosure meeting on august 2, 2024, is as follows.
eisai’s affiliates in china are wholly-owned by eisai co., ltd. (eisai), a japanese multinational pharmaceutical company with strong r&d capabilities, as global headquarter in tokyo and headquarter of china in shanghai.
eisai has grown smoothly since entering the chinese market in the early 1990s and the total …